Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Marinus Pharmaceuticals

< Previous 1 2 3 4 Next >
Marinus Pharmaceuticals Announces Publication in The Lancet Neurology of ZTALMY® (ganaxolone) Phase 3 Marigold Trial Results
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Bolsters Financial Position With Drawdown of $30 Million Under Oaktree Capital Credit Facility
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Announces FDA Approval of ZTALMY® (ganaxolone) for CDKL5 Deficiency Disorder
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Announces Delay to RAISE Phase 3 Clinical Trial in Status Epilepticus and Associated IV Ganaxolone Clinical Trials
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals to Provide Business Update and Announce Preliminary Fourth Quarter 2021 Financial Results on March 21, 2022
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Completes In Vivo M2 Metabolite Study and Provides European Regulatory Update
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference and H.C. Wainwright Bioconnect Conference
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Announces New Clinical and Research Data to be Presented at American Epilepsy Society Meeting
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Announces Nine Presentations and Virtual Investor Event at American Epilepsy Society 2021 Annual Meeting
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2021 Financial Results
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals to Provide Business Update and Announce Third Quarter 2021 Financial Results on November 9, 2021
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Joins the Loulou Foundation in Collaboration on CANDID, a Comprehensive Observational Study in CDKL5 Deficiency Disorder
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Provides Strategic Update at Virtual R&D Event
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Announces Virtual R&D Event on October 5, 2021
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Announces FDA Acceptance for Filing and Priority Review of New Drug Application for Ganaxolone in CDKL5 Deficiency Disorder
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Reports Topline Ganaxolone Phase 2 Open-Label Results in Tuberous Sclerosis Complex and Receives FDA Orphan Drug Designation
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2021 Financial Results
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals to Provide Business Update and Announce Second Quarter 2021 Financial Results on August 10, 2021
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Announces Exclusive Collaboration with Orion Corporation for European Commercialization of Ganaxolone
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Submits New Drug Application (NDA) to FDA for Ganaxolone for the Treatment of Seizures Associated with CDKL5 Deficiency Disorder and Provides Pipeline Update
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.